Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gains from Sales and Divestitures (2023 - 2025)

Harmony Biosciences Holdings' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $215795.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 59.85% year-over-year to $215795.0; the TTM value through Dec 2025 reached $215795.0, up 59.85%, while the annual FY2025 figure was $215795.0, 59.85% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $215795.0 at Harmony Biosciences Holdings, roughly flat from $215795.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $215795.0 in Q3 2025 and bottomed at $15000.0 in Q1 2024.
  • The 3-year median for Gains from Sales and Divestitures is $75760.5 (2023), against an average of $95325.5.
  • The largest annual shift saw Gains from Sales and Divestitures tumbled 50.0% in 2024 before it surged 1038.63% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $30000.0 in 2023, then skyrocketed by 350.0% to $135000.0 in 2024, then surged by 59.85% to $215795.0 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Gains from Sales and Divestitures are $215795.0 (Q4 2025), $215795.0 (Q3 2025), and $170795.0 (Q2 2025).